We Are a Research-Driven Biotechnology Company Focused on Targeted Cancer Therapies

Our Mission Is to Improve Therapeutic Outcomes for Patients Living with Cancer

Our Science Targets Tumor Hypoxia for the Treatment of Cancer

Our People Make the Difference

We Are Passionate About Our Mission and Determined to Achieve Success

We Believe that Better Outcomes are within Reach through Targeting Tumor Hypoxia

The Courage of People Living with Cancer Inspires Us to Work Harder

We Approach Our Work with Integrity, Transparency, Conviction, and Humility


Threshold is a clinical stage biopharmaceutical company focused on the discovery and development of cancer therapeutics based on a novel and powerful approach of targeting tumor hypoxia.

Clinical Trials

Clinical trials of TH-302 are enrolling patients with pancreatic cancer, non-squamous non-small cell lung cancer (n-s NSCLC), melanoma, multiple myeloma, glioblastoma, liver cancer, and kidney cancer. Read more.

You are now leaving this website. If you would like to continue, click Continue.